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Abstract
Background: Due to their favorable physical and biological properties, helium ion beams are increasingly considered a
promising alternative to proton beams for radiation therapy. Hence, this work aims at comparing in-silico the treatment of
brain and ocular meningiomas with protons and helium ions, using for the first time a dedicated Monte Carlo (MC) based
treatment planning engine (MCTP) thoroughly validated both in terms of physical and biological models.
Methods: Starting from clinical treatment plans of four patients undergoing proton therapy with a fixed relative biological
effectiveness (RBE) of 1.1 and a fraction dose of 1.8 Gy(RBE), new treatment plans were optimized with MCTP for both
protons (with variable and fixed RBE) and helium ions (with variable RBE) under the same constraints derived from the
initial clinical plans. The resulting dose distributions were dosimetrically compared in terms of dose volume histograms
(DVH) parameters for the planning target volume (PTV) and the organs at risk (OARs), as well as dose difference maps.
Results: In most of the cases helium ion plans provided a similar PTV coverage as protons with a consistent trend of
superior OAR sparing. The latter finding was attributed to the ability of helium ions to offer sharper distal and lateral
dose fall-offs, as well as a more favorable differential RBE variation in target and normal tissue.
Conclusions: Although more studies are needed to investigate the clinical potential of helium ions for different tumour
entities, the results of this work based on an experimentally validated MC engine support the promise of this modality
with state-of-the-art pencil beam scanning delivery, especially in case of tumours growing in close proximity of multiple
OARs such as meningiomas.
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Background
In comparison to conventional photon radiation, ion
beams offer favorable physical and biological properties,
which may enable maximizing the dose delivered to the
tumour volume, while reducing the dose to sensitive
organs at risk (OAR) and the integral dose to the
patient. To date, about 70 ion therapy facilities
worldwide treat patients with ion beams, predominantly
protons and, to a lower extent, carbon ions. However,
synchrotron-based multi-source facilities such as the
Heidelberg Ion Beam Therapy Center (HIT [1]) can offer
the possibility to produce and accelerate to therapeutic
energies additional ion species such as helium and
oxygen, thus making an initial evaluation of their
treatment effectiveness via in-silico treatment planning
studies highly desirable. In particular, compared to the
first clinical experience of helium ions with passively
scattered beam delivery at the Lawrence Berkeley
Laboratory [2, 3], modern facilities such as HIT can
provide fully active pencil beam scanning delivery.
For tumour entities, which do not necessarily
require an elevated linear energy transfer (LET) and
associated relative biological effectiveness (RBE) of
heavy ions, helium ions delivered with state-of-the-art
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techniques have the potential to improve clinical
outcome in comparison to the more broadly deployed
proton beams. In terms of physical interactions
properties, the reduced range and lateral straggling of
helium ions compared to protons [4, 5] can result in
superior healthy tissue sparing and improved dose-to-
target conformity. In terms of radiobiology, helium
ions exhibit a higher LET and therefore a higher RBE
than protons, as investigated in [6], as well as a
smaller oxygen enhancement ratio (OER). This trend
continues for heavier ions such as carbon that can
reach even higher LET values and correspondingly
higher RBE values, besides offering a reduced distal
and lateral straggling in comparison to helium ions.
Nevertheless, helium ions exhibit a favorably reduced
fragmentation tail after the Bragg peak compared to
heavier ions, thereby delivering lower dose distal to
the target [4]. Moreover, the variation in RBE between
tumor and normal tissue – the so called differential
effect – is reduced for helium ions compared to heavier
ions. Thus the lower range of RBE values makes
biological dose predictions of helium ions less prone to
uncertainties, particularly in normal tissue. Hence, all
these considerations make helium ions a promising
treatment option offering possibilities of dose escalation
compared to current clinical practice, owing to their
reduced penumbra compared to protons and their
lower dose fragmentation tail compared to heavier ions.
In particular, helium ion treatments could effectively
reduce dose to OARs located in proximity to the target,
as well as reduce the integral dose delivered to the
patient with the related risk of radiation-induced
secondary cancer. Vernimmen et al. [7] noted the
particular interest of proton beam therapy for complex
brain tumour entities, such as meningiomas. For these
indications, helium ions hold a great potential to
improve the therapeutic gain even further with respect
to proton therapy.
Due to the growing interest in helium ions as an
alternative to proton beams, recent works investigated
their advantages in in-silico treatment planning studies
[8–10], however relying on research platforms not
validated against experimental dosimetric data. To
overcome these limitations, we first performed a thor-
ough dosimetric characterization of helium ion beams
in water and air [4], as well as an in-depth validation of
the Monte Carlo (MC) code FLUKA [11] and the
related research tool for MC-based treatment planning
[5, 12, 13]. In a next step, our FLUKA-based calculation
framework was combined with a validated phenomeno-
logical biological model, previously benchmarked
against data for proton as well as helium ions, and
capable to account for the entire mixed radiation field
generated in nuclear interaction [14–16]. The use of
MC throughout and LET-based RBE modelling is an
advancement over previous publications [8–10]. This
way, we could develop the first thoroughly validated
(both in terms of physics and biological modeling)
treatment planning research platform, which has been
used in this work to perform a treatment plan compari-
son of four different brain and ocular meningioma
cases, using protons and helium ions.
Methods
Meningioma patient cases
Four meningioma patient cases treated at HIT with
protons, assuming a constant RBE of 1.1, were used in
this study. Details of each selected case are presented in
Table 1. In particular, our selection included:
– three cases of brain meningiomas irradiated with
two beams (patients A-C);
– one case of optical meningioma at shallow depth,
irradiated with a single beam (patient D).
The spatial locations of the critical OARs (cf. Table 1)
relative to the planning target volume (PTV) are displayed
in Fig. 1. The original proton plans from the commercial
Treatment Planning System (TPS, SyngoPT, Siemens)
were re-optimized with the FLUKA-based Monte-Carlo
treatment planning tool (MCTP [5, 12, 13]) for both
protons and helium ions, using a variable RBE model for
both ions, as well as a fixed RBE value of 1.1 for protons.
RBE of protons in clinical practice is defined at 1.1 [17],
since, as explained in [18], there are no sufficient in-vivo
data to support a variable RBE approach. However some
radiobiological studies especially in vitro with given cell
lines have shown a rise in RBE with the increase of LET
[16, 19], justifying the implementation of such variable
model in the MCTP.
For biological dose calculations using variable RBE
schemes, the αx and βx terms from the linear quadratic
equation [20] for photon irradiation need to be defined
for each tissue. However, with the biological model of
[15, 16] selected in this work, the αx/βx ratio is sufficient
to perform biological calculation. Two regions of interest
(ROIs) were distinguished for this study: the target
(PTV) and the OAR. For the non-tumorous regions, a
tissue type with an αx/βx ratio of 2.0 Gy [21] was chosen.
For the PTV, the tissue-type representing meningioma
was used, with an αx/βx ratio of 3.7 Gy, as recommended
in [22].
Optimization methods and dose calculation
The MCTP tool, presented in [13] for protons and in
[12] for carbon ions, was extended to helium ion
beams in this work. For treatment planning, physical
and biological optimization matrices were calculated
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from the initial TPS proton plans (i.e., same couch
positions, gantry angles, depths of the energy layers)
using the FLUKA code (development version 2016
[23–25]) in the voxelized geometry of the patient
computed tomography (CT) data with a voxel size of
1 × 1 × 3 mm3. From these plans and matrices, a first
optimization for protons with a fixed RBE of 1.1 was
performed to identify the best constraints on the
ROIs achieving similar or better dose volume histo-
grams (DVH) than the original plan from the analyt-
ical TPS. This approach has two main advantages: (1)
it makes the DVH results readily comparable to those
of the clinical TPS plans and (2) the biological dose
is not subject to variations when changing tissue type
or dose per fraction.
Optimizations with the identified constraints were
then performed for protons and helium ions taking into
account a phenomenological variable RBE approach
[14–16]. The ripple filter [26] was used for helium ions
to avoid possible target dose inhomogeneity, as seen for
shallow target depths in [5].
For the PTV, constraints to achieve a biological
dose of 1.8 Gy(RBE) per fraction were initially
applied, as well as a constraint on the maximum
Table 1 Proton plans characteristics for the considered patient
cases, as extracted from the TPS. The dose per fraction, number
of fractions and number of beams are reported. The table also
provides information on the angles between beams and the
OARs taken into account for the optimization
Patient Planned dose/
fraction
[Gy(RBE)]
Number
of fractions
Number
of beams
Angles
between
beams [°]
Critical
organ
at risks
A 1,8 29 2 180 Temporal lobes
(left/right)
Brain stem
Optical system
B 1,8 30 2 75 Brain stem
Chiasma
Optic nerves
(left/right)
Intra-auricular
nerve (right)
C 1,8 30 2 32 Brain stem
Chiasma
Optic nerve
(right)
D 1,8 28 1 \ Optic nerve
(left)
Eye (left)
Fig. 1 The four panels (a-d) display the complex relation between the contoured PTV and OARs for the four considered patient cases on the
X-ray computed tomography axial images (gray scale), with overlaid dose distributions (color wash) for proton plans of fixed RBE calculated with
MCTP. Second beam for patient B (panel b) is following the head-feet axis
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dose, where 5% or more of the volume (D5PTV)
should not receive more than 107% of the planned
dose. For the OAR, a constraint on D5OAR was set,
close to the D5OAR extracted from the DVH of the
TPS plan. The D5 was chosen instead of D2 to define
the maximum dose, since it was shown in [27] to be
less prone to statistical variation in MC simulations.
Additionally to the constraint on the OAR maximum
dose, low dose constraints were applied with smaller
optimization weights, to reduce as much as possible
the volume of OAR receiving low dose, and thereby
the integral dose by increasing the dose gradient
between PTV and surrounding normal tissue. In fact,
while multiple DVH constraints on dose and volumes
can be directly applied in the clinical TPS, this
feature is currently under development for the MCTP
tool.
After plan optimization, a final dose calculation was
performed for each case (i.e., protons with fixed or vari-
able RBE, helium ions with variable RBE) using 50 × 106
primary histories in 50 independent runs, at 1 × 1 ×
3 mm3 resolution. Dose distribution and DVH analysis
for plan comparisons were calculated and plotted with
an in-house software [28]. All considered parameters
were calculated for the full treatment dose, i.e., planned
target dose multiplied by the number of fractions (cf.
Table 1). In particular, the following DVH parameters
were extracted for plan evaluation of each ROI: D5, D10,
D20, D33, D50, D66, D75, D95.
Results
MCTP optimized plans in comparison to TPS plans for
protons at fixed RBE
The DVH results of proton optimization with fixed RBE
for the MCTP compared to the TPS are shown in
Table 2, representing the baseline dose difference
between dose volume parameters of the MCTP plans
against the TPS plans. For the PTV of the four patients,
the D5PTV value obtained with MCTP was found higher
by a maximum of about 2 Gy(RBE) compared to TPS.
However, overall a similar coverage of the target was
achieved, with on average less than 1.5 Gy(RBE) differ-
ence for all extracted DVH parameters. The maximum
deviation of 3 Gy(RBE) was found for the D95PTV of
patient A.
Regarding the OARs, a relatively good agreement in
terms of the maximum dose was obtained, with less
than 2.1 Gy(RBE) difference in the D5OAR. For the
other OAR DVH parameters, the difference between
MCTP and TPS was below 2 Gy(RBE), except for
patient D and the brainstem of patient B. For patient
D and the brainstem of patient B, MCTP was giving
higher dose on average to the OAR, up to
3.6 Gy(RBE) for the left eye of patient D. On the
other hand, the MCTP was able to reduce the dose
up to 10 Gy(RBE) in regions such as the optical sys-
tem of patient A. For this latter patient, all OARs in-
dicated a reduced dose with MCTP compared to the
TPS plan. For patient C, D5brainstem of brainstem was
Table 2 DVH parameters difference, in Gy(RBE), between the MCTP optimized proton plans with fixed RBE and the original TPS
plans for all the investigated ROIs of the four patients
DVH analysis: H (MCTPS, RBE = 1.1) - H (TPS, RBE = 1.1)
Patient ROI D5 D10 D20 D33 D50 D66 D75 D95
A PTV 2,0 1,7 1,2 0,9 0,6 0,0 0,0 -3,2
Temporal lobe left -4,1 −2,3 0,0 0,6 0,9 0,6 0,6 0,0
Temporal lobe right −6,7 −3,8 −4,4 −1,7 −1,5 −1,7 −2,0 −0,3
Brain stem −0,9 −2,0 −1,7 −1,5 −0,6 0,0 −0,3 0,0
Optical system −3,5 −4,9 −7,5 −9,9 −8,1 −5,2 −1,2 0,0
B PTV 1,5 0,9 0,3 0,6 0,3 0,3 0,3 −1,8
Optic nerve left −0,9 −1,5 −0,3 0,3 −0,3 0,0 0,0 −0,3
Chiasma 1,5 1,2 0,3 −1,8 −2,1 0,6 2,1 2,1
Optic nerve right 2,1 1,8 0,9 −0,9 −0,6 0,9 0,6 0,0
Brain stem −3,0 −5,1 −9,0 −5,4 1,5 3,6 2,7 0,9
C PTV 0,6 0,6 0,0 0,3 0,3 0,6 0,6 −0,9
Optic nerve (right) 1,2 1,5 1,2 0,6 0,9 0,9 0,9 1,8
Chiasma 0,3 0,0 −2,7 −9,0 −3,9 −5,4 −0,3 −0,3
Brain stem −9,6 −7,2 −1,5 0,9 0,3 0,0 0,0 −0,3
D PTV 2,0 1,7 1,4 0,6 0,3 0,3 0,3 1,1
Eye (left) 1,4 2,2 3,4 3,6 3,6 3,1 2,8 1,4
Optic nerve (left) −3,1 −2,5 −2,5 −0,8 2,8 3,4 2,8 0,8
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reduced by 9.6 Gy(RBE) with MCTP, and the D33chi-
asma of chiasma was about 9 Gy(RBE) lower. These
results are acceptable and demonstrate the treatment
planning capabilities of MCTP, providing improved
results than analytical TPS where possible, as also
seen in [13]. Regarding patient D, the higher dose
observed in the OAR can be attributed to the
difference in beam modeling at shallow depth
between TPS and MCTP. The TPS assumes a beam
spread smaller than the experimentally validated one
of MCTP, as seen in [29] for a patient suffering from
arteriovenous malformation (AVM), and in agreement
with the observations of [30] reporting similar
shortcomings for the same TPS system. Due to this
underestimation of the beam lateral size, the TPS
model predicts lower dose to OARs at shallow depth.
In contrast, the MCTP predicts a larger beam broad-
ening than TPS, consistently with experimental data
[29], and thus enhances the weight of the beams
delivering dose in the middle of PTV to provide a
good PTV coverage, while trying to fulfill OAR con-
straints. Although larger D5PTV values can be found
in the other patient cases, they are still respecting the
limits of 107% set in the constraints. Compared to
analytical TPS systems performing calculation in
water of variable depth, MC dose predictions gener-
ally exhibit higher D5PTV values as well as lowered
D95PTV values, due to the more realistic beam trans-
port in heterogeneous materials.
Comparison of MCTP optimized plans for protons and
helium ions
The dose distributions obtained with a variable RBE
scheme are exemplarily shown for patient A and D in
Figs 2 and 3, respectively, with the helium ion dose predic-
tion on top and the one for protons on the bottom. The
treatment plans for the other patients are reported in the
Additional file 1. The chosen dose display uses a color-
wash system showing selected dose level set to >10%,
>20%, >50%, >80%, >95% and >107% of the prescribed
dose. In Fig. 4 the difference between the planned dose
distributions are shown, with the top panel showing the
helium ions dose minus the protons one, while vice versa
in the bottom panel, with a color-wash system showing
the dose differences >3, >6, >9, >12, >15 and >18 Gy(RBE).
It can be seen that the 10%, 20% and 50% dose level re-
gions are broader for protons than for helium ions, as best
visualized in the dose difference maps. The dose gradients
Fig. 2 Planned dose distributions superimposed on the gray scale X-ray CT images are shown for patient A, featuring in the top panels helium
ions (4He) and in the bottom panels protons (1H) for the sagittal (left), coronal (middle) and axial (right) slices
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outside the target are sharper for helium ions than for
protons in all directions, as expected. In Fig. 2 for patient
A, some hotspots can be observed for helium ions outside
of the target volume or near the vicinity of the PTV. In
addition to the shallow dose gradient found for protons
for patient D, doses above 107% exist within the PTV for
the proton patient D plan (cf. also Fig. 5).
DVH plots for the different ROIs are displayed in
Fig. 5. Proton results are shown for both fixed (dot-
ted lines) and variable RBE (dashed lines). Helium
ions are displayed with solid lines. Tables 3 and 4
quantify the differences between DVH parameters
extracted from helium ion and proton plans, the
latter with either a fixed or variable RBE. As also
visible in Fig. 5, the PTV coverage reported in Tables
3 and 4 was found similar for all cases except
patient D, where helium ions afford better coverage,
with a sharper PTV DVH. For this patient D, the
D5PTV is larger with protons by about 2 Gy(RBE),
due to the hot spots previously mentioned. For most
of the dose volume parameters in OARs, the dose is
reduced with helium ions compared to protons with
a fixed RBE (Table 3), with dose sparing up to
7.5 Gy(RBE) for D95chiasma of Patient B. Only the
D5brainstem of patient C and D5Opt.Nerve/ D10Opt.Nerve
of patient D present higher doses above 2 Gy(RBE)
for helium ions, with values of about 3 Gy(RBE) and
3.9/2.5 Gy(RBE), respectively. When comparing
helium ions to protons with variable RBE, the
helium ion dose in OARs is reduced up to
7.8 Gy(RBE) for D50Opt.System of Patient A (Table 4).
Only the D5Opt.Nerve of patient D is exhibiting higher
dose with helium ions by about 1.7 Gy(RBE). Proton
plans optimized with variable RBE show in the
OARs a DVH slightly shifted toward higher dose,
about 1–2 Gy(RBE), compared to the plans optimized and
calculated with fixed RBE value. This trend can be particu-
larly seen for small volumes close to the PTV, for example
leading to higher D5/D10 values.
For patient D, as previously mentioned, the PTV
coverage was found better with helium ions, with a
larger D95PTV value and a smaller D5PTV value, which is
an indicator of PTV dose homogeneity. This finding is
ascribed to the small size of the target and the proximity
of the OAR. In fact, due to the larger lateral and distal
fall-off of proton beams, they cannot cover the target
optimally without impacting the surrounding OARs.
Thus, to provide a better coverage, the optimizer has to
choose to allocate higher doses in the middle of PTV for
protons, as seen in Fig. 3.
Compared to protons plans with variable RBE, helium
ions provide better sparing of OAR in all cases, exclud-
ing the left optic nerve of patient D. Since in this latter
case the left optic nerve is included in the PTV, higher
doses in the OAR are to be expected due to the above
mentioned better dose homogeneity within the PTV. In
general, the OAR DVH curves of helium ions are shifted
toward lower doses for two reasons. First, the reduced
lateral straggling positively impacts the DVH with a
reduced OAR dose, particularly when considering OARs
Fig. 3 Planned dose distributions superimposed on the gray scale X-ray CT images are shown for patient D, featuring in the top panels helium
ions (4He) and in the bottom panels protons (1H) for the sagittal (left), coronal (middle) and axial (right) slices
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volume above 1/3 of their total volume (Fig. 5). Second,
a more favorable ratio is found between the RBE at high
LET for αx/βx of 3.7 (target) and the RBE at low LET for
αx/βx of 2 (for the surrounding non-tumour tissue). This
RBE ratio between tumour and non-tumour tissue is in
the order of 15–20% larger for helium ions for the
studied cases, consistent with the model comparisons
reported by [31], thus leading to less deposited physical
dose than protons for the same prescribed biological
dose to the target. Even when compared to proton ir-
radiation with fixed RBE of 1.1, helium ions still present
the advantage of superior OAR dose sparing, since pro-
tons with fixed and variable RBE showed similar trends.
The largest differences between protons with variable
and fixed RBE can be seen for OARs at the end of the
beam range, where LET, and therefore RBE, is enhanced,
ultimately leading to higher biological dose deposition.
This latter case can be seen particularly for the chiasma
of patient C in Fig. 5.
Discussion
This work demonstrated the capabilities of the developed
MCTP framework to provide with proper constraints
sound treatment plans, comparable in quality to those ob-
tained from the clinical TPS for protons with fixed RBE.
The extension of MCTP to helium ions enabled perform-
ing an in-silico comparison with protons under realistic
conditions, using for the first time a MC-based treatment
planning platform thoroughly validated both in terms of
physics and biological models for both ion species. The re-
sults of this study confirmed the anticipated advantages of
helium ions over protons for meningioma cases at the
considered fraction dose of 1.8 Gy(RBE), showing similar
PTV coverage and better sparing of OAR for all beam
configurations investigated, featuring two fields (from op-
posing to small angles) as well as single field. The benefits
of both the physical advantages, in terms of improved lat-
eral and distal straggling, and the more favorable bio-
logical properties, in terms of enhanced RBE in the target
at the considered fraction dose, were particularly seen
when using a variable RBE scheme for both ions.
Although not shown in this work, similar advan-
tages were also observed when considering a hypo-
fractionated delivery of helium ions at 3 Gy(RBE)
dose per fraction, although the performance was
found dependent on the tissue-specific αx/βx ratio
Fig. 4 Dose difference between the helium ions and proton dose predictions for patient A: the top panel displays the overdosage due to helium
ions (i.e., the difference of 4He dose minus the proton dose), while the bottom panel shows the overdosage due to protons (i.e., 1H-4He). Colors
represent the dose >3, >6, >9, >12, >15 and >18 Gy(RBE) (from blue to red), for a 54Gy(RBE) total treatment dose
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Table 3 DVH parameters difference, in Gy(RBE), between the MCTP optimized helium plans with variable RBE (var. RBE) and proton
plans with fixed RBE for all the investigated ROIs of the four patients
DVH analysis: He (var. RBE) - H (RBE = 1.1)
Patient ROI D5 D10 D20 D33 D50 D66 D75 D95
A PTV −0,9 −1,2 −0,9 −0,6 −0,3 0,6 0,9 1,2
Temporal lobe left −2,9 −3,8 −3,8 −4,1 −4,1 −3,5 −3,5 −1,7
Temporal lobe right −1,2 −1,2 −1,5 −1,5 −1,7 −2,9 −2,9 −0,9
Brain stem −1,5 −1,5 −2,3 −2,9 −2,3 −3,5 −3,8 −2,0
Optical system 0,6 1,2 0,3 −2,0 −4,4 −4,6 −4,4 −1,7
B PTV −0,3 −0,3 0,3 −0,6 0,0 −0,3 −0,9 −0,6
Optic nerve left −3,3 −3,0 −3,6 −1,5 0,0 0,0 −0,3 0,0
Chiasma −1,2 −1,2 −0,9 −0,9 −2,1 −5,1 −6,3 −7,5
Optic nerve right −1,2 −1,2 −0,9 0,3 −4,2 −4,8 −2,1 −0,3
Brain stem −0,3 0,3 0,3 −3,0 −3,9 −3,3 −2,7 −0,6
C PTV −0,6 −0,6 0,0 0,0 0,6 0,0 0,3 −0,6
Optic nerve (right) −0,6 −1,2 −1,5 −1,5 −1,2 −1,5 −3,3 −6,0
Chiasma −2,4 −2,1 −0,6 2,1 0,9 0,9 1,5 0,9
Brain stem 3,0 0,0 −1,2 −1,5 0,0 0,0 0,0 0,0
D PTV −1,7 −1,1 −0,8 0,0 0,6 0,8 1,4 0,6
Eye (left) 0,6 −1,1 −3,1 −5,0 −6,4 −6,4 −6,4 −4,5
Optic nerve (left) 3,9 2,5 0,0 −3,6 −4,8 −3,6 −2,8 −0,8
Table 4 DVH parameters difference, in Gy(RBE), between the MCTP optimized helium plans and proton plans with variable RBE (var.
RBE) for all the investigated ROIs of the four patients
DVH analysis: He (var. RBE) - H (var. RBE)
Patient ROI D5 D10 D20 D33 D50 D66 D75 D95
A PTV −0,6 −0,9 −0,6 −0,3 0,0 0,3 0,6 0,6
Temporal lobe left −4,4 −4,6 −4,6 −4,1 −3,8 −3,5 −3,5 −2,0
Temporal lobe right −2,3 −1,5 −1,5 −1,5 −1,5 −2,6 −2,9 −0,9
Brain stem −3,8 −4,3 −5,2 −4,6 −3,5 −4,4 −5,2 −3,2
Optical system −0,6 −1,2 −3,2 −5,8 −7,8 −7,3 −5,8 −1,7
B PTV −0,3 −0,6 0,0 −0,3 0,0 0,0 0,0 −0,6
Optic nerve left −6,0 −6,0 −5,7 −2,4 −0,3 0,0 −0,3 0,0
Chiasma −0,9 −0,9 0,0 −0,3 −2,4 −5,1 −6,3 −7,8
Optic nerve right −0,6 −0,6 −0,6 −0,9 −6,0 −5,7 −2,1 −0,3
Brain stem 0,3 0,0 −2,1 −5,1 −6,0 −5,1 −4,2 −1,5
C PTV −0,6 −0,6 0,0 −0,3 0,0 0,0 0,3 −0,6
Optic nerve (right) −0,9 −0,9 −1,2 −1,2 −1,5 −3,6 −5,4 −6,9
Chiasma −1,2 −1,2 −0,9 −1,5 −3,3 −0,9 0,9 0,9
Brain stem −0,9 −4,2 −3,9 −2,7 −0,3 0,0 0,0 0,0
D PTV −2,5 −2,0 −1,1 −0,6 0,0 0,8 1,4 0,8
Eye (left) −0,3 −1,7 −3,4 −5,0 −6,4 −6,7 −7,0 −5,0
Optic nerve (left) 1,7 0,3 −2,8 −5,9 −6,4 −5,0 −3,9 −1,4
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[32]. Additional investigations for the shallow target
of patient D indicated that similar or even better
planning results could be obtained when omitting the
usage of the ripple filter, especially when introducing
a tighter separation of energy layers corresponding to
1 mm Bragg peak spacing in water, instead of the
typical separation of ~2 mm used by the TPS [32].
Conclusion
Helium ions can be considered a promising treatment
modality for low-grade meningiomas, where several
critical structures to be spared are surrounding the
tumour, and elevated RBE values are not necessarily
needed, in contrast to more aggressive high-grade
malignancies. Moreover, additional indications might
benefit from the above-mentioned advantages, and will
be further explored with the developed MCTP tool.
Additional investigations using tumor control probabil-
ity and normal tissue complication probability models or
robust planning, to take into account the planning and
delivery uncertainty, could also be of interest for a future
introduction of helium ion therapy in the clinical routine.
Efforts for tighter conformation of target-dose with better
sparing of normal tissue and OARs will also largely benefit
from the possibility of in-vivo verification, where
encouraging results of few millimeters localization accur-
acy have been recently reported with Positron-Emission-
Tomography [33, 34] and prompt gamma imaging [35],
especially for tumours located in the head.
Additional file
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